海外存託憑證基本資料檔-藥華藥

海外存託憑證基本資料檔公司代號:6446公司名稱:藥華藥上市地點代號:盧森堡存託機構名稱:花旗銀行有價證券之種類:普通股發行地點:盧森堡初次發行之日期-海外存託:20230418初次發行之數額-海外存託:34000000初次發行之股數-所表彰有價證券:34000000增發之數額-海外存託:0增發之股數-所表彰有價證券:0契約簽約日:20230418發行方式:全部公開發行是否供海外公司債轉換:N洽特定人認購之單位股數:0洽特定人總金額:0以現金增資發行新股發行海外股票者其募集資金運計畫及預計可能產生效益:(A)資金用途：充實營運資金及轉投資子公司PharmaEssentia USACorporation及PharmaEssentia Japan KK。(B)預計可能產生之效益：支應研發、臨床試驗所需資金及轉投資子公司以改善財務結構、降低營運風險及支持公司未來業務發展。對股東權益之主要影響:對股東權益之主要影響：本次現金增資發行普通股參與發行海外存託憑證之發行股數計34,000,000股 ，約佔增資後全部流通在外股份總數之10%，應不致對原股東權益造成重大影響。審酌本次現金增資之資金用途及預計可能產生效益，對本公司之長期發展應具正面效益，且對股東權益應尚無不利之影響。每單位價格:13.61發行金額:462740000每股價格:415申請日期:20230320核准日期:20230410申請發行金額:499761000保管機構:花旗(台灣)銀行承銷商:永豐金證券股份有限公司海外存託憑證所表彰有價證券之上市證券代號:6446存託機構名稱-英文:Citibank, N.A.有價證券之種類-英文:Common shares發行地點-英文:Luxembourg以現金增資發行新股發行海外股票者其募集資金運計畫及預計可能產生效益-英文:Use of proceeds: To strengthen the working capital structure of the Company and reinvest in the Company's subsidiaries, PharmaEssentia USA Corporation and PharmaEssentia Japan KK.Esimated benefits: To support research and development, clinicaltrials, and reinvest in subsidiaries to improve the financialstructure, reduce operational risk, and support future businessdevelopment of the Company.對股東權益之主要影響-英文:The number of new common shares ussued for cash capital increase for sponsoring issuance of GDSs is 34,000,000 shares, which represents approximately 10%of the total number of outstanding shares after the capital increase and should not cause a significant impact on the interests of the existing shareholders.Considering the use of proceeds and estimated benefitsof the capital increase, it shall have positive benefitson the Company's long-term development and no adverseeffect on shareholders' interests.保管機構-英文:Citibank Taiwan Limited承銷商-英文:SinoPac Securities Corporation